# A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

> **NCT07426380** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 28 (estimated)

## Conditions studied

- Kidney Disease
- Renal Insufficiency Chronic
- Kidney Failure, Chronic
- Renal Impairment
- Renal Insufficiency
- End Stage Kidney Disease

## Interventions

- **DRUG:** LY3841136

## Key facts

- **NCT ID:** NCT07426380
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07426380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07426380, "A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT07426380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*